Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Influenza
Biotech
Merck pays $9.2B for owner of flu antiviral J&J rejected
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.
James Waldron
Nov 14, 2025 8:25am
Fierce Pharma
Cidara snares BARDA award to boost R&D, production of flu asset
Oct 3, 2025 10:10am
Federal mRNA vax grant cuts includes unrelated project
Aug 7, 2025 2:20pm
Moderna's flu/COVID vaccine hit by deprioritization, FDA delay
May 1, 2025 7:24am
CDC data on influenza, bird flu go missing as outbreaks escalate
Feb 19, 2025 9:45am
AI drug discoverer's antiviral reduces COVID in mouse lungs
Jan 21, 2025 12:42am
